Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523654 | 0.84 | CPB2 (0.44) | CPB2CPB1SIRT2 | |
| SCHEMBL31006001 | 0.80 | KDM4E (0.37) | CPB2CPB1KDM4EALDH1A1 | |
| SCHEMBL27627317 | 0.80 | ALDH1A1 (0.45) | SIRT2ALDH1A1 | |
| SCHEMBL4418364 | 0.80 | ALDH1A1 (0.45) | SIRT2ALDH1A1 | |
| SCHEMBL24621004 | 0.75 | KDM4E (0.39) | CPB2CPB1KDM4EALDH1A1 | |
| SCHEMBL8347877 | 0.74 | CPB2 (0.54) | CPB2CPB1SIRT2 | |
| SCHEMBL23038508 | 0.74 | KDM4E (0.38) | CPB2CPB1KDM4EALDH1A1 | |
| SCHEMBL25836736 | 0.73 | CA1 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL8349511 | 0.73 | CPB2 (0.42) | CPB2CPB1SIRT2 | |
| SCHEMBL30455998 | 0.71 | CTSS (0.35) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8512675-B2 | N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination | MALLINCKRODT LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8512675-B2 | N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination | MALLINCKRODT LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20070077195-A1 | \"N and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3 (co)3]+ by fac coordination\ | UNIVERSITY OF ZURICH (CH) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077195-A1 | \"N and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3 (co)3]+ by fac coordination\ | CPN1, NUCB2, NAA15 | CPB2 376/4885CPB1 383/4885SIRT2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.